Overview

Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety of avelumab and AVB-S6-500 and see what effects (good and bad) this combination treatment has on patients with advanced urothelial carcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
University of Oklahoma
Collaborators:
Aravive Biologics
Aravive, Inc.
EMD Serono
Treatments:
Antibodies, Monoclonal
Avelumab